We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 08, 2021

Lenalidomide and Dexamethasone With or Without Clarithromycin in Patients With Multiple Myeloma Ineligible for Autologous Transplant

Blood Cancer Journal

 

Additional Info

Blood Cancer Journal
Lenalidomide and Dexamethasone With or Without Clarithromycin in Patients With Multiple Myeloma Ineligible for Autologous Transplant: A Randomized Trial
Blood Cancer J 2021 May 21;[EPub Ahead of Print], N Puig, MT Hernández, L Rosiñol, E González, F de Arriba, A Oriol, V González-Calle, F Escalante, J de la Rubia, M Gironella, R Ríos, R García-Sánchez, JM Arguiñano, A Alegre, J Martín, NC Gutiérrez, MJ Calasanz, ML Martín, MDC Couto, M Casanova, M Arnao, E Pérez-Persona, S Garzón, MS González, G Martín-Sánchez, EM Ocio, M Coleman, C Encinas, AM Vale, AI Teruel, M Cortés-Rodríguez, B Paiva, MT Cedena, JF San-Miguel, JJ Lahuerta, J Bladé, R Niesvizky, MV Mateos

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading